KR20220029763A - 신규한 항체 기본구조 - Google Patents

신규한 항체 기본구조 Download PDF

Info

Publication number
KR20220029763A
KR20220029763A KR1020227006072A KR20227006072A KR20220029763A KR 20220029763 A KR20220029763 A KR 20220029763A KR 1020227006072 A KR1020227006072 A KR 1020227006072A KR 20227006072 A KR20227006072 A KR 20227006072A KR 20220029763 A KR20220029763 A KR 20220029763A
Authority
KR
South Korea
Prior art keywords
sequence
human
seq
ser
framework region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227006072A
Other languages
English (en)
Korean (ko)
Inventor
세바스티안 메이어
데이비드 우레흐
Original Assignee
누맙 세러퓨틱스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 누맙 세러퓨틱스 아게 filed Critical 누맙 세러퓨틱스 아게
Priority to KR1020237043185A priority Critical patent/KR20240000622A/ko
Publication of KR20220029763A publication Critical patent/KR20220029763A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020227006072A 2013-06-26 2014-06-26 신규한 항체 기본구조 Ceased KR20220029763A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237043185A KR20240000622A (ko) 2013-06-26 2014-06-26 신규한 항체 기본구조

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13003264.2 2013-06-26
EP13003264 2013-06-26
PCT/EP2014/001730 WO2014206561A1 (en) 2013-06-26 2014-06-26 Novel antibody frameworks
KR1020217024096A KR20210097829A (ko) 2013-06-26 2014-06-26 신규한 항체 기본구조

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217024096A Division KR20210097829A (ko) 2013-06-26 2014-06-26 신규한 항체 기본구조

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043185A Division KR20240000622A (ko) 2013-06-26 2014-06-26 신규한 항체 기본구조

Publications (1)

Publication Number Publication Date
KR20220029763A true KR20220029763A (ko) 2022-03-08

Family

ID=48699516

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227006072A Ceased KR20220029763A (ko) 2013-06-26 2014-06-26 신규한 항체 기본구조
KR1020217024096A Ceased KR20210097829A (ko) 2013-06-26 2014-06-26 신규한 항체 기본구조
KR1020167001339A Active KR102286053B1 (ko) 2013-06-26 2014-06-26 신규한 항체 기본구조
KR1020237043185A Pending KR20240000622A (ko) 2013-06-26 2014-06-26 신규한 항체 기본구조

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020217024096A Ceased KR20210097829A (ko) 2013-06-26 2014-06-26 신규한 항체 기본구조
KR1020167001339A Active KR102286053B1 (ko) 2013-06-26 2014-06-26 신규한 항체 기본구조
KR1020237043185A Pending KR20240000622A (ko) 2013-06-26 2014-06-26 신규한 항체 기본구조

Country Status (12)

Country Link
US (3) US10174102B2 (enExample)
EP (1) EP3013864A1 (enExample)
JP (4) JP6708544B2 (enExample)
KR (4) KR20220029763A (enExample)
CN (2) CN105579472B (enExample)
AU (2) AU2014301629B2 (enExample)
CA (1) CA2914829A1 (enExample)
HK (1) HK1218549A1 (enExample)
IL (3) IL243311B (enExample)
NZ (1) NZ714320A (enExample)
SG (2) SG11201509899PA (enExample)
WO (1) WO2014206561A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220029763A (ko) 2013-06-26 2022-03-08 누맙 세러퓨틱스 아게 신규한 항체 기본구조
WO2016202457A1 (en) 2015-06-15 2016-12-22 Numab Ag Hetero-dimeric multi-specific antibody format
BR112018067696A2 (pt) 2016-02-25 2019-01-08 Cell Medica Switzerland Ag membros de ligação à pd-l1
KR102392746B1 (ko) 2016-03-17 2022-04-29 누맙 이노베이션 아게 항-TNFα-항체 및 이의 기능성 단편
LT3219726T (lt) 2016-03-17 2021-01-25 Tillotts Pharma Ag Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
SG11201808041UA (en) 2016-03-17 2018-10-30 Numab Innovation Ag ANTI-TNFa-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
MA43716A (fr) 2016-03-17 2018-11-28 Numab Innovation Ag Anticorps anti-tnf et fragments fonctionnels de ceux-ci
SI3219727T1 (sl) 2016-03-17 2021-04-30 Tillotts Pharma Ag Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
GB201621591D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Antibody molecules and method
AU2018280683B2 (en) 2017-06-05 2025-05-22 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US11365240B2 (en) 2017-06-05 2022-06-21 Numab Therapeutics AG Anti-HSA antibodies
CN110691789A (zh) 2017-06-05 2020-01-14 努玛治疗有限公司 新型抗cd3抗体
CN110799540B (zh) * 2017-06-25 2024-02-13 西雅图免疫公司 多特异性抗体及其制备和使用方法
CN116041530A (zh) 2017-06-25 2023-05-02 西雅图免疫公司 多特异性抗体及其制备和使用方法
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
EP4271413A4 (en) * 2020-12-30 2025-07-30 Ascendo Biotechnology Inc MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND ITS USES
KR20230146053A (ko) 2021-02-12 2023-10-18 베링거 인겔하임 인터내셔날 게엠베하 보체 c3 항원 결합 단백질
EP4305190A4 (en) 2021-03-11 2025-03-26 Iggenix, Inc. METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION
CN118434764A (zh) 2021-12-22 2024-08-02 Cdr生物科技股份有限公司 抗c3抗体及其抗原结合片段及其用于治疗眼疾病的用途
WO2024098026A2 (en) * 2022-11-04 2024-05-10 Mink Therapeutics, Inc. B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
CA2533830A1 (en) 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
KR20100028571A (ko) 2007-05-21 2010-03-12 앨더 바이오파마슈티컬즈, 인코포레이티드 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
CA2689941C (en) 2007-06-25 2019-10-29 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
MX345395B (es) * 2008-06-25 2017-01-30 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
KR101737466B1 (ko) * 2008-06-25 2017-05-18 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
US8193235B2 (en) 2009-06-12 2012-06-05 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
WO2011137362A1 (en) * 2010-04-30 2011-11-03 Rother Russell P Antibodies having reduced immunogenicity in a human
WO2012163519A1 (en) * 2011-05-27 2012-12-06 Dutalys Antibodies with improved folding stability
KR20220029763A (ko) 2013-06-26 2022-03-08 누맙 세러퓨틱스 아게 신규한 항체 기본구조
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations

Also Published As

Publication number Publication date
JP2019201643A (ja) 2019-11-28
US20230212265A1 (en) 2023-07-06
KR20240000622A (ko) 2024-01-02
KR20210097829A (ko) 2021-08-09
IL243311A0 (en) 2016-03-31
IL293477B1 (en) 2024-07-01
CN105579472B (zh) 2021-10-22
JP2024026176A (ja) 2024-02-28
JP2022028659A (ja) 2022-02-16
HK1218549A1 (zh) 2017-02-24
AU2014301629A1 (en) 2015-12-10
CN113943366A (zh) 2022-01-18
CN105579472A (zh) 2016-05-11
SG10201811017QA (en) 2019-01-30
IL293477A (en) 2022-08-01
US20190119359A1 (en) 2019-04-25
IL293477B2 (en) 2024-11-01
US11427628B2 (en) 2022-08-30
US20160130326A1 (en) 2016-05-12
IL313351A (en) 2024-08-01
WO2014206561A1 (en) 2014-12-31
CN113943366B (zh) 2024-12-13
NZ714320A (en) 2022-02-25
WO2014206561A8 (en) 2016-02-18
EP3013864A1 (en) 2016-05-04
JP6708544B2 (ja) 2020-06-10
AU2020202770A1 (en) 2020-05-14
AU2020202770B2 (en) 2023-01-05
JP2016523537A (ja) 2016-08-12
KR102286053B1 (ko) 2021-08-04
SG11201509899PA (en) 2016-01-28
IL243311B (en) 2022-07-01
US10174102B2 (en) 2019-01-08
CA2914829A1 (en) 2014-12-31
AU2014301629B2 (en) 2020-02-06
KR20160024923A (ko) 2016-03-07

Similar Documents

Publication Publication Date Title
US20230212265A1 (en) Novel antibody frameworks
US20230242651A1 (en) Stable antibody variable domain framework combinations
JP2016523537A5 (enExample)
US11365240B2 (en) Anti-HSA antibodies
HK40023336A (en) Anti-hsa antibodies
HK40023336B (en) Anti-hsa antibodies

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104